Cargando…
Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia
T cell acute lymphoblastic leukemia (T-ALL), a neoplasm derived from T cell lineage-committed lymphoblasts, is characterized by genetic alterations that result in activation of oncogenic transcription factors and the NOTCH1 pathway activation. The NOTCH is a transmembrane receptor protein activated...
Autores principales: | Chang, Yoon Soo, Gills, Joell J., Kawabata, Shigeru, Onozawa, Masahiro, Della Gatta, Giusy, Ferrando, Adolfo A., Aplan, Peter D., Dennis, Phillip A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609462/ https://www.ncbi.nlm.nih.gov/pubmed/37800623 http://dx.doi.org/10.3892/ijo.2023.5576 |
Ejemplares similares
-
A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors
por: Blumenthal, Gideon M., et al.
Publicado: (2014) -
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
por: Osoegawa, Atsushi, et al.
Publicado: (2017) -
Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells
por: Kawabata, S, et al.
Publicado: (2012) -
Targeting mTOR in Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2019) -
Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer
por: Kawabata, Shigeru, et al.
Publicado: (2014)